A Utah Rep., Brady Brammer, filed a bill that would establish a task force to research the therapeutic potential of psychedelics.
“Utah has some of the finest researchers in the areas of psychiatry and neurosciences at Huntsman Mental Health Institute,” he said. “This bill seeks to leverage that expertise, along with other experts grappling with mental illness, to review the research results, and if appropriate, make recommendations on how to safely administer these therapeutics under the care of qualified physicians.”
A Kansas legislator filed a bill to legalize the possession of up to 50 grams of psilocybin or psilocin, as well as the cultivation of psilocybin mushrooms. Possessing 50-100 grams would be considered a civil offense with a fine of up to $250. Possessing over 100 grams would be a misdemeanor with a fine of up to $500 and up to one month in jail.
If you’re looking to try microdosing, what better way to get started than with a community of like-minded individuals.
Dose Day is a microdosing peer support network that connects you with a small group with similar intentions and interests. Meet with your group weekly to see how the power of community can support you on your journey.
Whether you’re an artist, an executive, a consciousness junkie or someone looking to improve their mental health, there is a group for you.
Plus, half the fee supports palliative care patients with end-of-life anxiety. Click here to learn more.
Eleusis, a UK-based company focused on psilocybin therapy for depression, is planning to go public through a $446M merger with Silver Spike Acquisition Corp. II (SPKB). Eleusis will apply to have its shares listed on the NASDAQ under the symbol ‘ELEU’.
Algernon Pharmaceuticals (AGN) found that microdoses of DMT can increase the growth of neurons in the brain by up to 40%. An upcoming study will see if this can benefit stroke patients.
Phase I of the study, which is awaiting approval in the UK, will determine the maximum amount of DMT that can be taken without producing a psychedelic effect. Phase II will test repeated doses on acute and recovering stroke patients.
Numinus Wellness (NUMI) is enrolling patients for a multi-site study on MDMA for PTSD, which will be sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). The study received approval from both Health Canada and the Institutional Ethics Review Board.
Representatives from seven US states (Oregon, Nebraska, Michigan, Arizona, Texas, Minnesota, and Pennsylvania) have submitted a letter urging the Drug Enforcement Administration (DEA) to allow terminally-ill patients access to psilocybin treatments. The lawmakers believe that psilocybin qualifies as an investigational drug and should therefore be accessible through Right to Try laws.
University of Sydney researchers received $3M in funding from the Australian government to support MDMA and psilocybin studies! The MDMA study will investigate combined PTSD and alcohol use disorder, and the psilocybin study will be focused on anorexia nervosa.
In a preclinical animal model, Wesana Health (WESA) found that a single high dose of psilocybin rapidly improved depressive behaviours for 14 days. A regimen of psilocybin microdoses and CBD was able to sustain the results and reduced depressive behaviours by an additional 64%.